The hypothesis of study is addition of apalutamide to RT+ LHRHa provides superior efficacy in terms of PSMA-PET metastatic progression-free survival-ppMPFS.
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapyand LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients.
|Eligibility criteria|| |
|Study details|| |
Participants will be randomized (1:1 ratio) to receive either RT+LHRHa or RT+LHRHa plus apalutamideasthe study interventions. For this study, radiotherapy is defined as prostate-bed plus pelvic lymph node salvage external-beam radiotherapy (with or without optional SBRT for participants with ≤3 metastases).
|Further information|| |
For more information regarding this clinical trial click here.
NSW, QLD, WA